BR112017017182A2 - composto para tratamento de doenças ou condições por inibição da atividade ou expressão de gh, ghr, stat5, igf-1 e/ou socs e de proteínas reguladas por gh, ghr, stat5, socs, igf-1 e insulina humanos; compostos para tratamento de doenças ou condições por inibição da atividade ou expressão de gh, ghr, stat5, socs, igf-1 e insulina e de proteínas reguladas por gh, ghr, stat5, socs, igf-1 e insulina humanos; método para tratamento de doenças ou condições com alterações em genes da sinalização relacionados com gh, ghr, stat5 e socs humanos; e método para tratamento de doenças ou condições causadas por atividade de hormônios do crescimento - Google Patents

composto para tratamento de doenças ou condições por inibição da atividade ou expressão de gh, ghr, stat5, igf-1 e/ou socs e de proteínas reguladas por gh, ghr, stat5, socs, igf-1 e insulina humanos; compostos para tratamento de doenças ou condições por inibição da atividade ou expressão de gh, ghr, stat5, socs, igf-1 e insulina e de proteínas reguladas por gh, ghr, stat5, socs, igf-1 e insulina humanos; método para tratamento de doenças ou condições com alterações em genes da sinalização relacionados com gh, ghr, stat5 e socs humanos; e método para tratamento de doenças ou condições causadas por atividade de hormônios do crescimento

Info

Publication number
BR112017017182A2
BR112017017182A2 BR112017017182A BR112017017182A BR112017017182A2 BR 112017017182 A2 BR112017017182 A2 BR 112017017182A2 BR 112017017182 A BR112017017182 A BR 112017017182A BR 112017017182 A BR112017017182 A BR 112017017182A BR 112017017182 A2 BR112017017182 A2 BR 112017017182A2
Authority
BR
Brazil
Prior art keywords
ghr
stat5
socs
human
igf
Prior art date
Application number
BR112017017182A
Other languages
English (en)
Portuguese (pt)
Inventor
Wei Min
Neamati Nouri
Balasubramanian Priya
D Longo Valter
Original Assignee
Univ Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Southern California filed Critical Univ Southern California
Publication of BR112017017182A2 publication Critical patent/BR112017017182A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
BR112017017182A 2015-02-12 2016-02-12 composto para tratamento de doenças ou condições por inibição da atividade ou expressão de gh, ghr, stat5, igf-1 e/ou socs e de proteínas reguladas por gh, ghr, stat5, socs, igf-1 e insulina humanos; compostos para tratamento de doenças ou condições por inibição da atividade ou expressão de gh, ghr, stat5, socs, igf-1 e insulina e de proteínas reguladas por gh, ghr, stat5, socs, igf-1 e insulina humanos; método para tratamento de doenças ou condições com alterações em genes da sinalização relacionados com gh, ghr, stat5 e socs humanos; e método para tratamento de doenças ou condições causadas por atividade de hormônios do crescimento BR112017017182A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562115356P 2015-02-12 2015-02-12
PCT/US2016/017717 WO2016130901A2 (en) 2015-02-12 2016-02-12 Blockers of the growth hormone receptor in disease prevention and treatment

Publications (1)

Publication Number Publication Date
BR112017017182A2 true BR112017017182A2 (pt) 2018-04-03

Family

ID=56615057

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017017182A BR112017017182A2 (pt) 2015-02-12 2016-02-12 composto para tratamento de doenças ou condições por inibição da atividade ou expressão de gh, ghr, stat5, igf-1 e/ou socs e de proteínas reguladas por gh, ghr, stat5, socs, igf-1 e insulina humanos; compostos para tratamento de doenças ou condições por inibição da atividade ou expressão de gh, ghr, stat5, socs, igf-1 e insulina e de proteínas reguladas por gh, ghr, stat5, socs, igf-1 e insulina humanos; método para tratamento de doenças ou condições com alterações em genes da sinalização relacionados com gh, ghr, stat5 e socs humanos; e método para tratamento de doenças ou condições causadas por atividade de hormônios do crescimento

Country Status (14)

Country Link
US (2) US10246446B2 (enExample)
EP (1) EP3256465B1 (enExample)
JP (2) JP6930916B2 (enExample)
KR (1) KR20180016333A (enExample)
CN (1) CN107438605B (enExample)
AU (1) AU2016219173B2 (enExample)
BR (1) BR112017017182A2 (enExample)
CA (1) CA2976219C (enExample)
ES (1) ES2871551T3 (enExample)
IL (1) IL253943A0 (enExample)
MX (1) MX383010B (enExample)
NZ (1) NZ734252A (enExample)
RU (1) RU2726254C2 (enExample)
WO (1) WO2016130901A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11284640B2 (en) 2017-02-14 2022-03-29 University Of Southern California Fasting mimicking diet
CN112153974A (zh) 2018-03-15 2020-12-29 南加利福尼亚大学 禁食模仿膳食(fmd)而非仅饮水禁食促进炎症和ibd病理学的逆转

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9701010D0 (sv) * 1997-03-19 1997-03-19 Pharmacia & Upjohn Ab Antibody
JPWO2002096892A1 (ja) 2001-05-31 2004-09-09 小野薬品工業株式会社 オキサジアゾール誘導体化合物およびその化合物を有効成分とする薬剤
WO2006001770A1 (en) * 2004-06-28 2006-01-05 Biovitrum Ab Method for identifying modulators of cytokine class i receptor
RU2415134C9 (ru) * 2005-08-15 2011-05-27 Этерна Центарис ГмбХ Способ лечения или профилактики физиологических и/или патофизиологических состояний, опосредуемых рецепторами, стимулирующими секрецию гормона роста, триазолы и фармацевтическая композиция на их основе
US8519137B2 (en) 2007-10-11 2013-08-27 Vertex Pharmaceuticals Incorporated Heteroaryl amides useful as inhibitors of voltage-gated sodium channels
AU2008352540B2 (en) * 2008-03-14 2012-06-28 Biocon Limited A monoclonal antibody and a method thereof
JP5731501B2 (ja) * 2009-07-28 2015-06-10 コーニンクレッカ フィリップス エヌ ヴェ ロック構造を有するハウジング
RU2014123030A (ru) * 2011-12-22 2016-02-20 Ринат Ньюросайенс Корп. Антагонистические антитела против человеческого рецептора гормона роста и способы их применения
WO2013123511A1 (en) * 2012-02-16 2013-08-22 New York University Control of hypoxia-inducible gene expression with oligooxopiperazine nonpeptidic helix mimetics
WO2013192165A2 (en) 2012-06-20 2013-12-27 University Of Kansas Compounds and methods for activating the apoptotic arm of the unfolded protein response
KR20150124962A (ko) 2013-02-12 2015-11-06 유니버시티 오브 써던 캘리포니아 화학 독성 및 연령 관련 질병으로부터 보호하기 위한 방법 및 규정식

Also Published As

Publication number Publication date
US20190276445A1 (en) 2019-09-12
EP3256465A2 (en) 2017-12-20
CN107438605A (zh) 2017-12-05
MX2017010306A (es) 2018-03-15
US20170342063A1 (en) 2017-11-30
EP3256465B1 (en) 2021-04-07
CN107438605B (zh) 2021-03-19
RU2726254C2 (ru) 2020-07-10
AU2016219173A1 (en) 2017-08-17
RU2017129335A3 (enExample) 2019-08-07
CA2976219A1 (en) 2016-08-18
JP2018506534A (ja) 2018-03-08
NZ734252A (en) 2020-06-26
JP2021075553A (ja) 2021-05-20
EP3256465A4 (en) 2018-10-31
CA2976219C (en) 2021-05-04
WO2016130901A2 (en) 2016-08-18
WO2016130901A3 (en) 2016-10-20
ES2871551T3 (es) 2021-10-29
RU2017129335A (ru) 2019-03-12
KR20180016333A (ko) 2018-02-14
AU2016219173B2 (en) 2020-02-20
JP6930916B2 (ja) 2021-09-01
US10246446B2 (en) 2019-04-02
IL253943A0 (en) 2017-10-31
MX383010B (es) 2025-03-13

Similar Documents

Publication Publication Date Title
CL2024003661A1 (es) Anticuerpo anti-trem2 humano; método de producción; y su uso.
CY1124787T1 (el) Αντισωματα anti-gitr και μεθοδοι χρησης αυτων
BR112022003956A2 (pt) Anticorpos anti-cd73
UA116873C2 (uk) Антитіло, яке зв'язується з ox40
TN2014000513A1 (en) Dual receptor antagonistic antigen-binding proteins and uses thereof
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
AR104809A1 (es) Anticuerpos anti-cd40 y usos de los mismos
MX2022009625A (es) Receptores de antigenos quimericos condicionalmente activos para celulas t modificadas.
EA201790342A1 (ru) Антитела к trem2 и способы их применения
MY184154A (en) Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
BR112016014284A2 (pt) anticorpo caninizado isolado ou um fragmento de ligação de antígeno do mesmo, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para aumentar a atividade de uma célula imune e para produzir um anticorpo caninizado ou fragmento de ligação de antígeno do mesmo
UA115439C2 (uk) Гуманізоване антитіло, яке розпізнає альфа-синуклеїн
BR112017010094A2 (pt) anticorpos compreendendo regiões constantes de cadeias pesadas modificadas
UY36942A (es) Proteínas de unión a antígeno que activan el receptor de leptina
BR112019023990A2 (pt) Bis-octa-hidrofenantreno carboxamidas e conjugados de proteína das mesmas
UA118354C2 (uk) Антитіло до рецептора колонієстимулювального фактора (кфс-1r)
UA117097C2 (uk) Антитіло проти лігандів рецептора в1 брадикініну
BR112015033069A2 (pt) moduladores de receptor do hormônio de crescimento
BR112017022255A2 (pt) anticorpo humanizado ou humano isolado, molécula de ácido nucleico isolada, vetor, célula hospedeira, método para produzir um anticorpo, e composição farmacêutica
MX381731B (es) Antagonistas de proteina que interactua con el receptor nogo 2 que contiene repeticion rica en leucina y dominio de inmunoglobulina (lingo-2) para el tratamiento de afecciones que involucran neuronas motoras.
BR112016002401A2 (pt) métodos para reduzir as taxas de exacerbação de asma usando benralizumab
BR112017026535A2 (pt) composto de fórmula estrutural i, enantiômero isolado, composição farmacêutica, método para inibir atividade do transportador de monocarboxilato mct4, método para inibir seletivamente atividade do transportador de monocarboxilato mct4, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 e uso de um composto
BR112014014824A2 (pt) anticorpos antagonistas do receptor do hormônio de crescimento humano e métodos de uso dos mesmos
MX2015002465A (es) Anticuerpos monoclonales para mejorar o inhibir factor de crecimiento 1 similar a insulina (igf-1).
BR112022005039A2 (pt) Tratamento de hepatite alcoólica

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2709 DE 06-12-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.